Alumis completes $345 million stock offering at $17 per share

Alumis Inc. (NASDAQ: ALMS) closed an upsized public offering of 20,297,500 shares at $17.00 per share, generating approximately $345.1 million in gross proceeds before fees and expenses, the clinical-stage biopharmaceutical company announced.

The offering included the full exercise of underwriters' option to purchase an additional 2,647,500 shares. All shares were sold by the company, according to the press release statement.

Morgan Stanley, Leerink Partners, Cantor and Wells Fargo Securities served as joint book-running managers for the offering. Baird and Oppenheimer & Co. acted as co-lead managers.

The public offering was conducted under a shelf registration statement on Form S-3 that was filed with the Securities and Exchange Commission and became effective on August 19, 2025.

South San Francisco-based Alumis develops targeted therapies for immune-mediated diseases. The company's pipeline includes oral tyrosine kinase 2 inhibitors, with envudeucitinib in development for systemic immune-mediated disorders including moderate-to-severe plaque psoriasis and systemic lupus erythematosus. The pipeline also includes A-005 for neuroinflammatory and neurodegenerative diseases, and lonigutamab, a subcutaneous therapy for thyroid eye disease.

You May Also Be Interested In

• TXNM Energy prices $400 million stock offering at $56.50 per share
• Yum! Brands completes Pizza Hut sale to LongRange for $1.5B
• Profound Medical names Richard Fabian as president